MedTrace Logo

TReating Incontinence for Underlying Mental and Physical Health

NCT05362292 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 270

Last updated 2026-03-06

No results posted yet for this study

Summary

The TRIUMPH study is a randomized, double-blinded, 3-arm, parallel-group trial designed to compare the effects of anticholinergic bladder therapy versus a) beta-3-adrenergic agonist bladder therapy and b) no bladder pharmacotherapy on cognitive, urinary, and other aging-related functional outcomes in ambulatory older women with urgency-predominant urinary incontinence and either normal or mildly impaired cognitive function at baseline.

Conditions

Interventions

DRUG

Tolterodine Tartrate ER

Anticholinergic

DRUG

Mirabegron

Beta-3-adrenergic agonist

DRUG

Placebo

matching placebo pill

Sponsors & Collaborators

Principal Investigators

  • Alison Huang, MD, MAS, MPhil · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-04
Primary Completion
2027-05-02
Completion
2027-08-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05362292 on ClinicalTrials.gov